Respiratory Infections

A new case series report highlights the unique circumstances of infant illness associated with COVID-19.

New data suggests informed, practical pooled testing could improve both public health response and clinical assessment of the pandemic.

The VRBPAC voted 20-0 with 1 abstention to support the benefit-risk profile associated with mRNA-1273.

While the number of study participants was too small to extrapolate for the whole population, the authors said they were encouraged.

Influenza and pneumonia, though rare, occurred at roughly the same rate in both the high-dose and standard-dose vaccine groups.

A universal flu vaccine is also another step closer, according to researchers at Mount Sinai.

The updated vaccine efficacy and safety outcomes include 37,000-plus participants from the ongoing, multi-national trial.

Investigators identify gene expression which may explain the highly transmissible nature of the virus.

Previous studies with influenza in animals demonstrated antiviral efficacy was not species restricted.

Physicians are beginning to find key patterns which will aid public health in the future.

Cincinnati, Ohio-based Blue Water Vaccines is working on developing a vaccine that will permanently protect against current and future influenza strains.

COVID-19 is a dynamic disease which evolves as it disrupts host programs and rewires modules.

LabCorp, an early adopter with extensive geographic reach, will be the first lab offering the test in the United States.

Recent study may have implications for social and public health policies

New study may help contribute to COVID-19 research.

Patients with pervasive conditions are found to be more at risk for a severe case of COVID-19.

Articles not undergoing peer review are reaching widespread dissemination during the pandemic. What are the implications?

Researchers find most common mutations appear to have been induced by the human immune system.

A study author at Keck Medicine of USC discusses an ongoing assessment of LY-CoV555 for preventing severe COVID-19, and the overall benefit of the drug class for pandemic mitigation.

The former FDA commissioner weighs in on the best measures to mitigate skyrocketed new cases, and his timeline for national recovery.

Important finding shows convalescent plasma provides no significant benefit in severe COVID-19 cases.

Recent study shows COVID-19 survivors health improves with support of Home Health Care.

An artificial intelligence (AI) algorithm predicts outcomes in patients diagnosed with COVID-19.

New study provides deep insights into the COVID-19 pandemic.